Arecor Therapeutics plc (LON:AREC – Get Free Report) shares traded down 3.1% during trading on Friday . The stock traded as low as GBX 60.12 and last traded at GBX 61.50. Approximately 59,482 shares changed hands during mid-day trading, an increase of 201% from the average session volume of 19,749 shares. The stock had previously closed at GBX 63.50.
Arecor Therapeutics Stock Performance
The company has a 50-day simple moving average of GBX 64.09 and a two-hundred day simple moving average of GBX 69.29. The company has a debt-to-equity ratio of 1.52, a quick ratio of 6.24 and a current ratio of 4.35. The firm has a market capitalization of £23.22 million, a P/E ratio of 30.75 and a beta of -0.18.
About Arecor Therapeutics
Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel’s twiist™ AID system.
Further Reading
- Five stocks we like better than Arecor Therapeutics
- Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
- Apple’s Record Quarter Could Not Outrun Its Guidance Problem
- McKesson’s Compounding Keeps Adding Up
Receive News & Ratings for Arecor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arecor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
